Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

BioNeutra Global Corporation

Company price
0.0056 USD 0.00(0%)
Last update at 2026-11-19T21:00:00Z
VOLUME
313
Market Cap
0.26M

Momentum Score

…

BioNeutra Global Corporation engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products with a focus on oligosaccharides. The company offers isomalt oligosaccharide ingredients under the VitaFiber brand for human digestive health. It operates in Canada, the United States, Australia, New Zealand, European Union, and the Asia Pacific. The company is headquartered in Vancouver, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.07
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public filings for BioNeutra Global Corporation (Pink: BGACF) are limited, and the company's current operating activities and product lines are not well documented in publicly available sources. Given the sparse disclosure, long-term growth drivers are unclear, though investors may find exposure to a small-cap company with potential upside if commercial activities scale or transparency improves.

Key investment risks include very limited disclosure and reporting, thin market liquidity, operational and regulatory uncertainty, and heightened share-price volatility associated with Pink-listed microcap issuers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
10.86M
Revenue Per Share
0.23
Gross Profit TTM
4.65M
Debt / Equity
-1.23
ROE
-255.35%
Net Debt
5.75M
ROCE
-143.44%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -2.11M -2.92M -2.83M -3.77M -13.02M
Net income -2.11M -2.92M -2.83M -3.71M -12.44M
Selling general administrative 3.73M 3.78M 4.49M 5.43M 8.38M
Selling and marketing expenses 0.39M 0.14M 0.43M 0.36M 0.81M
Gross profit 4.14M 2.35M 2.89M 3.94M 0.64M
Reconciled depreciation 1.07M 1.11M 1.32M 1.84M 2.32M
Ebit -1.41M -2.47M -2.44M -3.34M -9.83M
Ebitda -0.35M -1.36M -1.12M -1.50M -7.51M
Depreciation and amortization 1.06M 1.11M 1.32M 1.84M 2.32M
Operating income -0.89M -2.47M -2.35M -3.02M -9.83M
Other operating expenses 12.27M 15.86M 17.76M 27.14M 47.53M
Interest expense 0.70M 0.45M 0.39M 0.43M 0.60M
Tax provision 0.00M 0.00M -0.00M -0.06M -0.58M
Interest income 0.01M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.65M -0.45M -0.39M -0.43M -0.59M
Income tax expense -1.10M 0.45M 0.39M -0.06M -0.58M
Total revenue 11.38M 13.39M 15.40M 24.12M 37.70M
Total operating expenses 4.14M 4.82M 5.25M 6.97M 10.47M
Cost of revenue 7.24M 11.04M 12.51M 20.17M 37.06M
Total other income expense net -1.22M -0.50M -0.47M -0.75M -2.59M
Net income from continuing ops -4.71M -2.92M -2.83M -3.71M -12.44M
Net income applicable to common shares - - -2.83M -3.71M -12.44M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 15.77M 19.78M 21.08M 23.68M 34.02M
Intangible assets 0.32M 0.43M 0.40M 0.64M 1.13M
Other current assets 0.57M - - - -
Total liab 21.96M 23.54M 22.12M 22.98M 29.27M
Total stockholder equity -6.19M -3.76M -1.03M 0.70M 4.75M
Other current liab 1.39M - 1.10M 1.12M 1.37M
Common stock 7.55M - 7.55M 7.55M 7.55M
Capital stock 7.55M 7.55M 7.55M 7.55M 7.55M
Retained earnings -16.05M -13.95M -11.02M -8.19M -4.49M
Other liab - - - 0.03M 0.06M
Cash 1.89M 0.72M 0.84M 0.93M 0.52M
Total current liabilities 14.78M 16.91M 15.78M 16.61M 22.53M
Current deferred revenue 0.05M - - - -
Net debt 5.75M 6.11M 6.05M 6.14M 7.06M
Short term debt 0.46M - - - -
Short long term debt 0.38M 0.30M 0.55M 0.74M 0.90M
Short long term debt total 7.64M - - - -
Other stockholder equity 1.81M - 1.12M 0.02M 0.55M
Property plant equipment - - 9.75M 10.59M 12.26M
Total current assets 6.97M 9.71M 10.93M 12.45M 20.64M
Long term investments - - - - 0.00M
Net tangible assets - - -1.43M 0.06M 3.63M
Short term investments 0.00M - - - -
Net receivables 1.22M 1.04M 1.73M 1.64M 3.30M
Long term debt 7.16M 6.53M 6.34M 6.33M 6.68M
Inventory 3.29M 7.18M 8.02M 7.85M 14.81M
Accounts payable 12.93M 15.43M 14.12M 14.75M 20.26M
Accumulated other comprehensive income 0.50M - - - -
Non current assets total 8.79M 10.07M 10.15M 11.23M 13.39M
Capital lease obligations 0.10M 0.18M - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 0.01M -0.20M -0.28M -0.03M 0.28M
Change to liabilities - - -0.65M -5.39M 7.94M
Total cashflows from investing activities - - -0.28M -0.03M 0.28M
Net borrowings - - 0.05M -0.51M -1.38M
Total cash from financing activities 0.45M -0.31M -0.30M -0.90M -1.66M
Change to operating activities - - 1.68M -0.39M -0.41M
Net income -2.11M -2.92M -2.83M -3.71M -12.44M
Change in cash 1.17M -0.12M -0.09M 0.41M -0.97M
Begin period cash flow 0.72M 0.84M 0.93M 0.52M 1.50M
End period cash flow 1.89M 0.72M 0.84M 0.93M 0.52M
Total cash from operating activities 0.68M 0.84M 0.27M 1.43M 0.71M
Issuance of capital stock - - - 0.00M 0.25M
Depreciation 1.06M 1.11M 1.32M 1.84M 2.32M
Other cashflows from investing activities - - - - 0.52M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory 3.89M 0.84M -0.17M 6.96M -1.74M
Change to account receivables -0.12M 0.63M -0.09M 1.66M 0.64M
Other cashflows from financing activities -0.66M -0.44M -0.35M -0.39M -0.53M
Change to netincome - - 1.00M 0.46M 0.10M
Capital expenditures 0.02M 0.20M 0.28M 0.08M 0.24M
Change in working capital 1.70M 2.44M 0.78M 2.84M 10.72M
Stock based compensation - 0.00M 0.48M 0.00M 0.01M
Other non cash items 0.04M 0.21M 0.52M 0.46M 0.52M
Free cash flow 0.66M 0.63M -0.01M 1.36M 0.47M

Peer Comparison*

Sector: Consumer Defensive Industry: Packaged Foods

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
BGACF
BioNeutra Global Corporation
-
-%
0.01 - - 0.02 - 1.00 11.23
NSRGF
Nestle SA
-
-%
99.03 26.86 18.76 3.13 7.10 3.81 21.70
NSRGY
Nestle SA ADR
0.85
0.85%
101.06 26.82 18.66 3.18 7.07 3.81 21.70
DANOY
Danone PK
-0.03
0.20%
14.93 24.23 17.64 1.88 2.57 1.88 11.70
GPDNF
Danone S.A
-
-%
74.00 20.30 14.75 1.65 2.24 1.76 10.92

Profile*

BioNeutra Global Corporation

BioNeutra Global Corporation engages in the research and development, production, and commercialization of food for nutraceutical, functional, and mainstream food and beverage products with a focus on oligosaccharides. The company offers isomalt oligosaccharide ingredients under the VitaFiber brand for human digestive health. It operates in Canada, the United States, Australia, New Zealand, European Union, and the Asia Pacific. The company is headquartered in Vancouver, Canada.

1030 West Georgia St., Vancouver, BC, Canada, V6E 2Y3

604-210-5669

Name Title Year Born
Dr. Jianhua Zhu Ph.D. Founder, CEO, Pres & Director NA
Mr. Yiyuan Jiang Chief Financial Officer NA
Mr. Ross Montagano Chief Operating Officer NA
Vinti Goel Ph.D. VP of Scientific & Regulatory Affairs NA
Sheri O'Brien VP of Sales & Marketing NA
Monica Barclay Corp. Sec. NA
Dr. Jianhua Zhu Ph.D. Founder, CEO, President & Director NA
Dr. Stephen C. Jakeway Ph.D. Chief Operating Officer NA
Vinti Goel Ph.D. Vice President of Scientific & Regulatory Affairs NA
Mr. Dario Mejia Vice President of Sales & Business Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…